source
- Iambic Therapeutics targets $135M IPO to fund clinical trials of HER2 and KIF18A cancer drugsIambic Therapeutics, a San Diego AI‑driven biotech, filed to raise $135 million in net proceeds through an initial public offering. The company plans to sell 9.4 million shares at $15 to $17 each,…
- Roche signs near-$1 billion partnership with Chinese biotech Defand on degrader therapiesRoche has entered into a new collaboration with Defand, a relatively unknown biotech based in Hangzhou, China. The agreement is the fourth China-focused deal the Swiss drugmaker has signed since Au…